Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
SWOG Cancer Research Network
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01416688
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.
PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.
PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.
Intervention
assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
Condition
Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Investigators
Laurence H. Baker, DO, FACOI